Common use of Additional Information and Where to Find It Clause in Contracts

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a tender offer for the outstanding shares of Zynerba. The tender offer has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Zynerba, nor is it a substitute for the tender offer materials that Harmony and Xylophone Acquisition Corp. (“Purchaser”) will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Harmony and Purchaser will file tender offer materials on Schedule TO, and Zynerba will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents) and the Solicitation/Recommendation Statement when they become available (as each may be amended or supplemented from time to time) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their shares. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of shares of Zynerba at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at wxx.xxx.xxx. In addition, these materials will be available at no charge on the Enhanced SEC Filings section of the Investor Relations page of Zxxxxxx’s website at wxx.xxxxxxx.xxx and by directing a request to the information agent for the tender offer, whose contact information will be set forth in the Offer to Purchase.

Additional Information and Where to Find It. In connection with The delisting offer described in this communication (the proposed acquisition, Hxxxxxx will commence a tender offer for the outstanding shares of Zynerba. The tender offer “Delisting Offer”) has not yet commenced. This document is for informational purposes only and communication is neither an offer to purchase nor a solicitation of an offer to sell shares of Zynerba, nor is it a substitute for MorphoSys AG (the tender “Company”). The final terms and further provisions regarding the Delisting Offer will be in the offer materials that Harmony and Xylophone Acquisition Corp. document once the publication of the offer document by Novartis BidCo AG (the “PurchaserBidder”) has been approved by the German Federal Financial Supervisory Authority (the “BaFin”), after which the offer document will be filed with the U.S. Securities and Exchange Commission (the “SEC”). A solicitation and an offer to buy shares of the Company will be made only pursuant the offer document. In connection with the Delisting Offer, the Bidder and Novartis AG will file a Tender Offer Statement on Schedule TO with the SEC upon commencement (together with the offer document, an Offer to Purchase including the means to tender and other related documents, the “Delisting Offer Documents”), the Company’s management board and supervisory board will issue a joint reasoned statement in accordance with sec. 27 of the tender offer. At German Securities Acquisition and Takeover Act and the time the tender offer is commenced, Harmony and Purchaser will file tender offer materials on Schedule TO, and Zynerba Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC (together with respect the joint reasoned statement, the “Recommendation Statements”). THE COMPANY’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE DELISTING OFFER DOCUMENTS AND THE RECOMMENDATION STATEMENTS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE DELISTING OFFER. The Delisting Offer Documents and the Recommendation Statements will be distributed to all stockholders of the tender offerCompany in accordance with German and U.S. securities laws. Holders of shares of Zynerba common stock are urged to read the tender offer materials (including an The Tender Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents) Statement on Schedule TO and the Solicitation/Recommendation Statement when they become available (as each may be amended or supplemented from time to time) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their shares. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of shares of Zynerba at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement on Schedule 14D-9 will be made available for free at the SEC’s website at wxx.xxx.xxxxxx.xxx.xxx. In addition, Additional copies may be obtained for free by contacting the Bidder or the Company. Free copies of these materials and certain other offering documents will be made available at no charge on the Enhanced SEC Filings section of the Investor Relations page of ZxxxxxxCompany’s website in English at wxx.xxxxxxx.xxx xxxxxxxxx.xxx/xx/xxxxxxxxx/Xxxxxxxx-XxxxxxxxXxxxx and in German at xxxxxxxxx.xxx/xx/xxxxxxxxxx/Xxxxxxxx-XxxxxxxxXxxxx, by directing a request mail to the information agent for the tender offerMorphoSys AG, whose contact information will be set forth in the Offer to PurchaseXxxxxxxxxxxxxxxxx 0, 00000 Xxxxxxx, Xxxxxxx or by phone at +00 00 0000 0000.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a The tender offer for all of the outstanding shares of Zynerba. The tender offer common stock of Xxxxx referenced in this document has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares securities of ZynerbaXxxxx, nor is it a substitute for the tender offer materials that Harmony and Xylophone Acquisition Corp. (“Purchaser”) Parent, Purchaser or Xxxxx will file with the SEC upon commencement SEC. The solicitation and offer to buy the common stock of Xxxxx will only be made pursuant to an Offer to Purchase and related tender offer materials that Parent and Purchaser intend to file with the tender offerSEC. At the time the tender offer is commenced, Harmony Parent and Purchaser will file tender offer materials with the SEC a Tender Offer Statement on Schedule TO, and Zynerba thereafter Xxxxx will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read the tender offer materials XXXXX’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ CAREFULLY THE TENDER OFFER MATERIALS (including an Offer to PurchaseINCLUDING AN OFFER TO PURCHASE, a related Letter of Transmittal and certain other tender offer documentsA RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) and the SolicitationAND THE SOLICITATION/Recommendation Statement when they become available (as each may be amended or supplemented from time to time) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their sharesRECOMMENDATION STATEMENT ON SCHEDULE 14D-9 BECAUSE THEY WILL EACH CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF XXXXX SECURITIES AND OTHER INVESTORS SHOULD CONSIDER BEFORE MAKING ANY DECISION WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and Transmittal, certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Statement will be made available to all holders stockholders of shares of Zynerba Xxxxx at no expense to them. The tender offer materials them and the Solicitation/Recommendation Statement will also be made available for free at the SEC’s website at wxx.xxx.xxxxxx.xxx.xxx. In addition, these materials Additional copies may be obtained for free by contacting either Parent or Xxxxx. Copies of the documents filed with the SEC by Xxxxx will be available at no free of charge on the Enhanced SEC Filings section of the Investor Relations page of ZxxxxxxXxxxx’s website at wxx.xxxxxxx.xxx and xxx.Xxxxxxxxxxxxxxxx.xxx or by directing a request to the information agent for the tender offer, whose contact information will be set forth in the Offer to Purchasecontacting Xxxxx’s Investor Relations Department at XxxxxxxxXxxxxxxxx@Xxxxxxxxxxxxxxxx.xxx or XX@Xxxxxxxxxxxxxxxx.xxx.

Additional Information and Where to Find It. This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. In connection with the proposed acquisitionmerger, Hxxxxxx NTN Buzztime intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will commence contain a tender offer for the outstanding shares proxy statement and a prospectus of ZynerbaNTN Buzztime, which joint proxy statement/prospectus will be mailed or otherwise disseminated to NTN Buzztime stockholders if and when it becomes available. INVESTORS AND SECURITY HOLDERS OF NTN BUZZTIME ARE URGED TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT BROOKLYN, NTN BUZZTIME, THE PROPOSED MERGER, AND RELATED MATTERS. The tender offer has not yet commenced. This document is for informational purposes only joint proxy statement/prospectus and is neither an offer to purchase nor a solicitation of an offer to sell shares of Zynerba, nor is it a substitute for the tender offer materials that Harmony and Xylophone Acquisition Corp. (“Purchaser”) will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Harmony and Purchaser will file tender offer materials on Schedule TO, and Zynerba will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read the tender offer other relevant materials (including an Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents) and the Solicitation/Recommendation Statement when they become available (as each available), and any other documents filed by NTN Buzztime with the SEC, may be amended or supplemented from time to time) because they will contain important information that holders obtained free of shares of Zynerba common stock should consider before making any decision regarding tendering their shares. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of shares of Zynerba at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free charge at the SEC’s SEC website at wxx.xxx.xxx. In addition, these materials will be available at no charge on the Enhanced SEC Filings section investors and security holders may obtain free copies of the Investor Relations page of Zxxxxxx’s website at wxx.xxxxxxx.xxx and documents filed with the SEC by NTN Buzztime by directing a written request to: NTN Buzztime, Inc, 6000 Xx Xxxxxx Xxxx, Xxxxx 000-Xxx 000, Xxxxxxxx, Xxxxxxxxxx 00000. Investors and security holders are urged to read the proxy statement, prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the information agent proposed merger. NTN Buzztime and its directors, executive officers and certain other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from the stockholders of NTN Buzztime with respect to the proposed merger and related matters. Information about the directors and executive officers of NTN Buzztime, including their ownership of shares of NTN Buzztime common stock, is included in NTN Buzztime’s Annual Report on Form 10-K for the tender offeryear ended December 31, whose contact 2019 and Amendment No. 1 thereto, which were filed with the SEC on March 19, 2020 and April 27, 2020, respectively. Additional information regarding the persons or entities who may be deemed participants in the solicitation of proxies from NTN Buzztime stockholders, including a description of their interests in the proposed merger by security holdings or otherwise, will be set forth included in the Offer joint proxy statement/ prospectus and other relevant documents to Purchasebe filed with the SEC when they become available. The managers and officers of Brooklyn do not currently hold any interests, by security holdings or otherwise, in NTN Buzztime.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a tender offer for the outstanding shares of Zynerba. The tender offer described in this communication has not yet commenced. This document is for informational purposes only and communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ZynerbaKite Pharma, nor is it a substitute for the tender Inc. (“Kite”). A solicitation and an offer to buy shares of Kite will be made only pursuant to an offer to purchase and related materials that Harmony and Xylophone Acquisition Corp. Gilead Sciences, Inc. (“PurchaserGilead”) will intends to file with the SEC upon commencement of the tender offerU.S. Securities and Exchange Commission (“SEC”). At the time the tender offer is commenced, Harmony and Purchaser Gilead will file tender offer materials a Tender Offer Statement on Schedule TOTO with the U.S. Securities and Exchange Commission, and Zynerba Kite will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock Kite stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents) and the Solicitation/Recommendation Statement when they become available (Statement, as each may be amended or supplemented from time to time) , because they will contain important information that holders of shares of Zynerba common stock which should consider be read carefully before making any decision regarding tendering their sharesis made with respect to the tender offer. The In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made Kite files annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Xxxx at the SEC public reference room at 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. Please call the SEC at 0-000-XXX-0000 for further information on the public reference room. Kite’s filings with the SEC are also available to all holders of shares of Zynerba at no expense to them. The tender offer materials the public from commercial document-retrieval services and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website maintained by the SEC at wxx.xxx.xxxxxx.xxx.xxx. In addition, these materials will be available at no charge on the Enhanced SEC Filings section Investors and security holders may also obtain free copies of the Investor Relations page of Zxxxxxx’s website documents filed with the SEC by Xxxx at wxx.xxxxxxx.xxx and by directing a request to the information agent for the tender offer, whose contact information will be set forth in the Offer to Purchasexxx.xxxxxxxxxx.xxx.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a The tender offer for the outstanding shares of Zynerba. The tender offer Nimble Storage common stock (the “Offer”) has not yet commenced. This document communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Zynerbashares, nor is it a substitute for the tender offer materials that Harmony and Xylophone Acquisition Corp. Hewlett Packard Enterprise Company (“PurchaserHPE”) and a subsidiary of HPE (“Merger Sub”) will file with the SEC upon commencement of U.S. Securities and Exchange Commission (the tender offer“SEC”). At the time the tender offer is commenced, Harmony HPE and Purchaser Merger Sub will file tender offer materials on Schedule TO, and Zynerba thereafter Nimble Storage will file a Solicitation/Recommendation Statement on Schedule 14D-9 14D-9, with the SEC with respect to the tender offerOffer. Holders of shares of Zynerba common stock are urged to read the tender offer materials THE TENDER OFFER MATERIALS (including an Offer to PurchaseINCLUDING AN OFFER TO PURCHASE, a related Letter of Transmittal and certain other tender offer documentsA RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) and the SolicitationAND THE SOLICITATION/Recommendation Statement when they become available RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. HOLDERS OF SHARES OF NIMBLE STORAGE COMMON STOCK ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (as each may be amended or supplemented from time to timeAS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their sharesBECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF SHARES OF NIMBLE STORAGE COMMON STOCK SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of shares of Zynerba Nimble Storage’s common stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at wxx.xxx.xxxxxx.xxx.xxx. In addition, these materials will be available at no charge on the Enhanced SEC Filings section Additional copies of the Investor Relations page of Zxxxxxx’s website at wxx.xxxxxxx.xxx and tender offer materials may be obtained for free by directing a written request to the information agent for the tender offerNimble Storage, whose contact information will be set forth in Inc., 000 Xxxxx Xxxx Xxxxxxx, Xxx Xxxx, Xxxxxxxxxx 00000, Attn: Investor Relations, or by telephone at (000) 000-0000. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, HPE and Nimble Storage file annual, quarterly and current reports and other information with the SEC. You may read and copy any reports or other information filed by HPE or Nimble Storage at the SEC public reference room at 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. Please call the SEC at 0-000-XXX-0000 for further information on the public reference room. HPE’s and Nimble Storage’s filings with the SEC are also available to the public from commercial document-retrieval services and at the SEC’s website at xxx.xxx.xxx.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a The tender offer for the outstanding shares of Zynerba. The tender offer Nimble Storage common stock (the “Offer”) has not yet commenced. This document communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Zynerbashares, nor is it a substitute for the tender offer materials that Harmony HPE and Xylophone Acquisition Corp. a subsidiary of HPE (“PurchaserMerger Sub”) will file with the SEC upon commencement of U.S. Securities and Exchange Commission (the tender offer“SEC”). At the time the tender offer is commenced, Harmony HPE and Purchaser Merger Sub will file tender offer materials on Schedule TO, and Zynerba thereafter Nimble Storage will file a Solicitation/Recommendation Statement on Schedule 14D-9 14D-9, with the SEC with respect to the tender offerOffer. Holders of shares of Zynerba common stock are urged to read the tender offer materials THE TENDER OFFER MATERIALS (including an Offer to PurchaseINCLUDING AN OFFER TO PURCHASE, a related Letter of Transmittal and certain other tender offer documentsA RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) and the SolicitationAND THE SOLICITATION/Recommendation Statement when they become available RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. HOLDERS OF SHARES OF NIMBLE STORAGE COMMON STOCK ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (as each may be amended or supplemented from time to timeAS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their sharesBECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF SHARES OF NIMBLE STORAGE COMMON STOCK SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of shares of Zynerba Nimble Storage’s common stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at wxx.xxx.xxxxxx.xxx.xxx. In addition, these materials will be available at no charge on the Enhanced SEC Filings section Additional copies of the Investor Relations page of Zxxxxxx’s website at wxx.xxxxxxx.xxx and tender offer materials may be obtained for free by directing a written request to the information agent for the tender offerNimble Storage, whose contact information will be set forth in Inc., 000 Xxxxx Xxxx Xxxxxxx, Xxx Xxxx, Xxxxxxxxxx 00000, Attn: Investor Relations, or by telephone at (000) 000-0000. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, HPE and Nimble Storage file annual, quarterly and current reports and other information with the SEC. You may read and copy any reports or other information filed by HPE or Nimble Storage at the SEC public reference room at 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. Please call the SEC at 0-000-XXX-0000 for further information on the public reference room. HPE’s and Nimble Storage’s filings with the SEC are also available to the public from commercial document-retrieval services and at the SEC’s website at xxx.xxx.xxx.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a tender offer for the outstanding shares of Zynerba. The tender offer has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Zynerba, nor is it a substitute for the tender offer materials that Harmony and Xylophone Acquisition Corp. (“Purchaser”) will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Harmony and Purchaser will file tender offer materials on Schedule TO, and Zynerba will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents) and the Solicitation/Recommendation Statement when they become available (as each may be amended or supplemented from time to time) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their shares. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of shares of Zynerba at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at wxx.xxx.xxx. In addition, these materials will be available at no charge on the Enhanced SEC Filings section of the Investor Relations page of Zxxxxxx’s website at wxx.xxxxxxx.xxx and by directing a request to the information agent for the tender offer, whose contact information will be set forth in the Offer to Purchase.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a The tender offer for the outstanding shares of Zynerba. The tender offer common stock of Dunkin’ Brands described in this communication has not yet commenced. This document communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of ZynerbaDunkin’ Brands common stock, nor is it a substitute for the any tender offer materials that Harmony and Xylophone Acquisition Corp. (“Purchaser”) Inspire Brands, Inc., Vale Merger Sub, Inc. or Dunkin’ Brands will file with the SEC upon commencement U.S. Securities and Exchange Commission (the “SEC”). A solicitation and offer to buy shares of Dunkin’ Brands common stock will be made only pursuant to an offer to purchase and related materials that Inspire Brands, Inc. intends to file with the tender offerSEC. At the time the tender offer is commenced, Harmony and Purchaser Inspire Brands, Inc. will cause Vale Merger Sub, Inc. to file a tender offer materials statement on Schedule TOTO with the SEC, and Zynerba Dunkin’ Brands will file a Solicitationsolicitation/Recommendation Statement recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read XXXXXX’ BRANDS’ STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER TENDER OFFER DOCUMENTS) AND THE RELATED SOLICITATION/ RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY XXXXXX’ BRANDS WITH THE SEC, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO THAT SHOULD BE READ CAREFULLY. Both the tender offer materials (including an Offer to Purchasestatement and the solicitation/recommendation statement will be made available at no charge on the SEC’s website: xxx.xxx.xxx. In addition, a related Letter copy of Transmittal the offer to purchase, letter of transmittal and certain other tender offer documents) and the Solicitation/Recommendation Statement when documents (once they become available (as each available) will be mailed to Dunkin’ Brands stockholders free of charge and additional copies may be amended obtained free of charge, by contacting Dunkin’ Brands Investor Relations either by telephone at 000-000-0000 or supplemented from time by e-mail at Xxxxxxxx.Xxxxxxxxx@XxxxxxXxxxxx.xxx or on Dunkin’ Brands’ website at xxx.xxxxxxxxxxxx.xxx. In addition to time) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their shares. The Offer the offer to Purchasepurchase, the related Letter letter of Transmittal transmittal and certain other tender offer documents, as well as the Solicitationsolicitation/Recommendation Statementrecommendation statement, will be made Dunkin’ Brands files annual, quarterly and current reports, proxy statements and other information with the SEC. Dunkin’ Brands’ filings with the SEC are available to all holders of shares of Zynerba at no expense to them. The tender offer materials the public from commercial document-retrieval services and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website maintained by the SEC at wxx.xxx.xxxxxx.xxx.xxx. In addition, these materials will be available at no charge on the Enhanced SEC Filings section Investors and security holders may also obtain free copies of the Investor Relations page of Zxxxxxx’s website documents filed with the SEC by Dunkin’ Brands at wxx.xxxxxxx.xxx and by directing a request to the information agent for the tender offer, whose contact information will be set forth in the Offer to Purchasexxx.xxxxxxxxxxxx.xxx.

Additional Information and Where to Find It. In connection with the proposed acquisitionacquisition of Collectors Universe, Hxxxxxx Cards Acquisition Inc. (“Cards”), will commence a tender offer for all of the outstanding shares of ZynerbaCollectors Universe. The tender offer has not yet commenced. This document communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Zynerba, nor Collectors Universe. It is it also not a substitute for the tender offer materials that Harmony and Xylophone Acquisition Corp. (“Purchaser”) Cards will file with the SEC Securities and Exchange Commission (the “SEC”) upon commencement of the tender offer. At the time that the tender offer is commenced, Harmony and Purchaser Cards will file tender offer materials on Schedule TOTO with the SEC, and Zynerba Collectors Universe will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY COLLECTORS UNIVERSE’S SHAREHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents) and the Solicitationsolicitation/Recommendation Statement when they become available (as each may be amended or supplemented from time to time) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their shares. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, recommendation statement will be made available to all holders Collectors Universe’s shareholders free of shares charge. A free copy of Zynerba at no expense to them. The the tender offer materials and the Solicitationsolicitation/Recommendation Statement recommendation statement will also be made available for free at the SECto Collectors Universe’s shareholders by visiting Collectors Universe’s website at wxx.xxx.xxx(wxx.xxxxxxxxxxxxxxxxxx.xxx). In addition, these the tender offer materials and the solicitation/recommendation statement (and all other documents filed by Collectors Universe with the SEC) will be available at no charge on the Enhanced SEC Filings section of the Investor Relations page of ZxxxxxxSEC’s website at wxx.xxxxxxx.xxx and by directing a request to (wxx.xxx.xxx) upon filing with the information agent for the tender offerSEC. COLLECTORS UNIVERSE’S SHAREHOLDERS ARE ADVISED TO READ THE TENDER OFFER MATERIALS AND THE SOLICITATION/RECOMMENDATION STATEMENT, whose contact information will be set forth in the Offer to PurchaseAS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED BY CARDS OR COLLECTORS UNIVERSE WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER. THESE MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TENDER OFFER, CARDS AND COLLECTORS UNIVERSE.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a tender offer for the outstanding shares of Zynerba. The tender offer described in this communication has not yet commenced. This document communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of ZynerbaIntercept Pharmaceuticals, Inc. (the “Company”), nor is it a substitute for the any tender offer materials that Harmony and Xylophone Acquisition Corp. the Company or Alfasigma S.p.A. (together with its subsidiaries, “PurchaserAlfasigma”) will file with the SEC upon commencement SEC. A solicitation and an offer to buy shares of the tender offerCompany will be made only pursuant to an offer to purchase and related materials that Alfasigma intends to file with the SEC. At the time the tender offer is commenced, Harmony and Purchaser Alfasigma will file tender offer materials a Tender Offer Statement on Schedule TOTO with the SEC, and Zynerba the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read the tender offer materials THE COMPANY’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (including an Offer to PurchaseINCLUDING AN OFFER TO PURCHASE, a related Letter of Transmittal and certain other tender offer documentsA RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) and the SolicitationAND THE SOLICITATION/Recommendation Statement when they become available (as each may be amended or supplemented from time to time) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their sharesRECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available sent to all holders stockholders of shares of Zynerba the Company at no expense to them. The tender offer materials Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at wxx.xxx.xxx. In addition, Additional copies may be obtained for free by contacting Alfasigma or the Company. Free copies of these materials and certain other offering documents will be made available by the Company by mail to Intercept Pharmaceuticals, Inc., 300 Xxxxxxx Xxxxxx, Xxxxxxxxxx, XX 00000, Attention: Corporate Secretary, by email at no charge on the Enhanced SEC Filings section of the Investor Relations page of Zxxxxxx’s website at wxx.xxxxxxx.xxx and ixxxxxxxx@xxxxxxxxxxxxxxx.xxx, or by directing a request requests for such materials to the information agent for the tender offer, whose contact information which will be set forth named in the tender offer materials. Copies of the documents filed with the SEC by the Company will be available free of charge under the “Investors & Media” section of the Company’s internet website at hxxxx://xx.xxxxxxxxxxxxxxx.xxx/xxxxxxxx-relations. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, the Company files periodic reports and other information with the SEC. The Company’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at wxx.xxx.xxx.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a The tender offer for the outstanding shares common stock of Zynerba. The tender offer Con-way has not yet commenced. This document is for informational purposes only and is neither does not constitute an offer to purchase nor buy or a solicitation of an offer to sell shares any securities of Zynerba, nor is it a substitute for the tender Con-way. The solicitation and offer materials that Harmony to buy common stock of Con-way will only be made pursuant to an Offer to Purchase and Xylophone Acquisition Corp. (“Purchaser”) will file with the SEC upon commencement of the tender offerrelated materials. At the time the tender offer is commenced, Harmony XPO and Purchaser Merger Subsidiary will file tender offer materials on Schedule TO, TO with the SEC and Zynerba Con-way will file a Solicitation/Recommendation Statement statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read the The tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents) and the Solicitation/Recommendation Statement will contain important information. Investors are urged to read these materials when they become available (available, as each may be amended or supplemented from time to time) well as any other relevant documents filed with the SEC, carefully and in their entirety because they will contain important information that holders information, including the terms and conditions of shares of Zynerba common stock should consider before making any decision regarding tendering their sharesthe offer. The Offer to Purchase, Purchase and the related Letter letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of shares of Zynerba Con-way at no expense to them. The Offer to Purchase and the related letter of Transmittal and certain other tender offer materials and documents, as well as the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at wxx.xxx.xxx. In additionAdditional copies may be obtained, these materials will be available at no charge free of charge, through the investor relations page on the Enhanced SEC Filings section of the Investor Relations page of ZxxxxxxXPO’s corporate website at wxx.xxxxxxx.xxx and wxx.xxxxxxxxxxxx.xxx or by directing a request contacting XPO Logistics, Inc. at Five Greenwich Office Park, Greenwich, CT 06831, Attention: Investor Relations. In addition to the information agent for the tender offer, whose contact information will be set forth in the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, XPO and Con-way file annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by XPO or Con-way at the SEC public reference room at 100 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. Please call the Commission at 1-800-SEC-0330 for further information on the public reference room. XPO and Con-way’s filings with the SEC are also available at the SEC’s website wxx.xxx.xxx.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a The tender offer for the outstanding shares of Zynerba. The tender offer common stock of NGM Bio referenced in this communication has not yet commenced. This document communication is for informational purposes only only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell shares of Zynerba, nor common stock of NGM Bio or any other securities. This communication is it also not a substitute for the tender offer materials that Harmony and Xylophone Acquisition Corp. (“Purchaser”) Purchaser will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Harmony and Purchaser will file tender offer materials with the SEC a Tender Offer Statement on Schedule TOTO and a Transaction Statement on Schedule 13E-3 (“Schedule 13E-3”), and Zynerba NGM Bio will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with and a Schedule 13E-3. NGM BIO’S STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION / RECOMMENDATION STATEMENT AND THE SCHEDULES 13E-3 WHEN SUCH DOCUMENTS BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. When filed, NGM Bio’s stockholders and other investors can obtain the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read the tender offer materials (including an Tender Offer to PurchaseStatement, a related Letter of Transmittal and certain other tender offer documents) and the Solicitation/Recommendation Statement when they become available (as each may be amended or supplemented from time to time) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their shares. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of shares of Zynerba at no expense to them. The tender offer materials the Schedules 13E-3 and the Solicitation/Recommendation Statement will be made available other filed documents for free at the SEC’s website at wxx.xxx.xxxxxx.xxx.xxx. Copies of the documents filed with the SEC by NGM Bio will be available free of charge on the Investors & Media page of NGM Bio’s website, xxx.xxxxxx.xxx, or by contacting NGM Bio at xx@xxxxxx.xxx. In addition, these materials will be available at no charge on the Enhanced SEC Filings section NGM Bio’s stockholders may obtain free copies of the Investor Relations page of Zxxxxxx’s website at wxx.xxxxxxx.xxx and tender offer materials by directing a request to contacting the information agent for the tender offer, whose contact information offer that will be set forth named in the Tender Offer to PurchaseStatement.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence This communication relates to a tender offer for the outstanding shares of Zynerbapending business combination between Biosynex and Chembio. The tender offer referenced in this communication has not yet commenced. This document communication is for informational purposes only and is neither does not constitute an offer to purchase nor or a solicitation of an offer to sell shares of ZynerbaChembio, nor is it a substitute for the any tender offer materials that Harmony and Xylophone Acquisition Corp. (“Purchaser”) the parties will file with the SEC U.S. Securities and Exchange Commission (the “SEC”) upon commencement of the tender offer. At the time the tender offer is commenced, Harmony Biosynex and Purchaser its acquisition subsidiary will file a tender offer materials statement on Schedule TO, including an offer to purchase, a letter of transmittal and Zynerba related documents, and Chembio will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders Each of shares of Zynerba common stock are urged Biosynex and Chembio also plan to read file other relevant documents with the tender offer materials SEC regarding the proposed transaction. CHEMBIO STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER MATERIALS (including an Offer to PurchaseINCLUDING AN OFFER TO PURCHASE, a related Letter of Transmittal and certain other tender offer documents) and the A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION / RECOMMENDATION STATEMENT AND OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO ANY OF THE FOREGOING DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF CHEMBIO SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Solicitation/Recommendation Statement when they become available (as each may be amended or supplemented from time to time) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their shares. The Statement, the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, documents will be made available sent to all holders of shares of Zynerba Chembio’s stockholders at no expense to them. The tender offer materials and the Solicitation/Solicitation / Recommendation Statement will also be made available for free at on the SEC’s website at wxx.xxx.xxxxxx.xxx.xxx or from the information agent named in the tender offer materials. In addition, these materials Copies of the documents filed with the SEC by Biosynex will be available at no free of charge on under the Enhanced SEC Filings section News heading of the Investor Relations page of ZxxxxxxBiosynex’s website at wxx.xxxxxxx.xxx and xxxxx://xxx.xxxxxxxx.xxx. Copies of the documents filed with the SEC by directing a request to the information agent for the tender offer, whose contact information Chembio will be set forth in available free of charge under the Offer to PurchaseSEC filings heading of the Investors section of Chembio’s website at xxxxx://xxxxxxx.xxx/investors.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a tender offer for the outstanding shares of Zynerba. The tender offer described in this communication has not yet commenced. This document is for informational purposes only and communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ZynerbaKite Pharma, nor is it a substitute for the tender Inc. (“Kite”). A solicitation and an offer to buy shares of Kite will be made only pursuant to an offer to purchase and related materials that Harmony and Xylophone Acquisition Corp. Gilead Sciences, Inc. (“PurchaserGilead”) will intends to file with the SEC upon commencement of the tender offerU.S. Securities and Exchange Commission (“SEC”). At the time the tender offer is commenced, Harmony and Purchaser Gilead will file tender offer materials a Tender Offer Statement on Schedule TO, TO with the SEC and Zynerba Kite will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock Kite stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents) and the Solicitation/Recommendation Statement when they become available (Statement, as each may be amended or supplemented from time to time) , because they will contain important information that holders of shares of Zynerba common stock which should consider be read carefully before making any decision regarding tendering their sharesis made with respect to the tender offer. The In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made Kite files annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Xxxx at the SEC public reference room at 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. Please call the SEC at 0-000-XXX-0000 for further information on the public reference room. Kite’s filings with the SEC are also available to all holders of shares of Zynerba at no expense to them. The tender offer materials the public from commercial document-retrieval services and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website maintained by the SEC at wxx.xxx.xxxxxx.xxx.xxx. In addition, these materials will be available at no charge on the Enhanced SEC Filings section Investors and security holders may also obtain free copies of the Investor Relations page of Zxxxxxx’s website documents filed with the SEC by Xxxx at wxx.xxxxxxx.xxx and by directing a request to the information agent for the tender offer, whose contact information will be set forth in the Offer to Purchasexxx.xxxxxxxxxx.xxx.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a tender offer for the outstanding shares of Zynerba. The tender offer referenced in this communication has not yet commenced. This document announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Zynerbasecurities, nor is it a substitute for the tender offer materials that Harmony and Xylophone Acquisition Corp. (“Purchaser”) will file be filed with the SEC upon commencement of the SEC. The solicitation and offer to buy AdvancePierre Foods stock will only be made pursuant to an Offer to Purchase and related tender offeroffer materials. At the time the tender offer is commenced, Harmony Tyson and Purchaser its acquisition subsidiary will file a tender offer materials statement on Schedule TO, TO and Zynerba thereafter AdvancePierre Foods will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read the tender offer materials THE TENDER OFFER MATERIALS (including an Offer to PurchaseINCLUDING AN OFFER TO PURCHASE, a related Letter of Transmittal and certain other tender offer documentsA RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) and the SolicitationAND THE SOLICITATION/Recommendation Statement when they become available (as each may be amended or supplemented from time to time) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their sharesRECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. ADVANCEPIERRE FOODS STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF ADVANCEPIERRE FOODS SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of shares of Zynerba AdvancePierre Foods stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s 's website at wxx.xxx.xxxxxx.xxx.xxx. In addition, these materials Copies of the documents filed with the SEC by Tyson will be available at no free of charge on the Enhanced SEC Filings section Xxxxx’x internet website at xxxx://xxx.xxxxx.xxx or by contacting Xxx Xxxxxx at Xxxxx’x Investor Relations Department at (000) 000-0000 or by email at xxx.xxxxxx@xxxxx.xxx. Copies of the documents filed with the SEC by AdvancePierre Foods will be available free of charge on AdvancePierre Foods’ internet website at xxxx://xxx.xxxxxxxxxxxxx.xxx or by contacting Xxxx Xxxxxx at AdvancePierre Foods’ Investor Relations page of Zxxxxxx’s website Department at wxx.xxxxxxx.xxx and (000) 000-0000 or by directing a request to the information agent for the tender offer, whose contact information will be set forth in the Offer to Purchaseemail at xx@xxxxxxxxxxxxx.xxx.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a tender offer for the outstanding shares of Zynerba. The tender offer described in this document has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of ZynerbaImmunomedics, nor is it a substitute for the any tender offer materials that Harmony and Xylophone Acquisition Corp. (“Purchaser”) Gilead, Purchaser or Immunomedics will file with the SEC upon commencement SEC. A solicitation and an offer to buy shares of Immunomedics will be made only pursuant to an offer to purchase and related materials that Gilead intends to file with the tender offerSEC. At the time the tender offer is commenced, Harmony and Purchaser Gilead will file tender offer materials a Tender Offer Statement on Schedule TOTO with the SEC, and Zynerba Immunomedics will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read the tender offer materials IMMUNOMEDICS’ STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (including an Offer to PurchaseINCLUDING AN OFFER TO PURCHASE, a related Letter of Transmittal and certain other tender offer documentsA RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) and the SolicitationAND THE SOLICITATION/Recommendation Statement when they become available (as each may be amended or supplemented from time to time) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their sharesRECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available sent to all holders stockholders of shares of Zynerba Immunomedics at no expense to them. The tender offer materials Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website web site at wxx.xxx.xxxxxx.xxx.xxx. In addition, Additional copies may be obtained for free by contacting Gilead or Immunomedics. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 000 Xxxxxxxx Xxxxx, Xxxxxx Xxxx, XX 00000, attention: Investor Relations, by phone at no charge on the Enhanced SEC Filings section of the Investor Relations page of Zxxxxxx’s website at wxx.xxxxxxx.xxx and 0-000-XXXXXX-0 or 0-000-000-0000, or by directing a request requests for such materials to the information agent for the tender offer, whose contact information which will be set forth named in the Tender Offer to PurchaseStatement. Copies of the documents filed with the SEC by Immunomedics will be available free of charge under the “Investors” section of Immunomedics’ internet website at Xxxxxxxxxxxx.xxx.

Additional Information and Where to Find It. In connection with the proposed acquisition, Hxxxxxx will commence a The tender offer for the outstanding shares of Zynerba. The tender offer the Company described in this communication has not yet commenced. This document communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Zynerbaany securities, nor is it a substitute for the tender offer materials that Harmony Wonder and Xylophone Acquisition Corp. (“Purchaser”) its acquisition subsidiary will file with the SEC Securities and Exchange Commission (“SEC”) upon commencement of the tender offer. The solicitation and offer to buy outstanding shares of the Company will only be made pursuant to the tender offer materials that Wonder and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced, Harmony and Purchaser will file tender offer materials on Schedule TO, and Zynerba Wonder will file a Solicitationtender offer statement on Schedule TO with the SEC, and the Company will file a solicitation/Recommendation Statement recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer. Holders of shares of Zynerba common stock are urged to read the THE COMPANY’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO CAREFULLY READ THE TENDER OFFER MATERIALS, INCLUDING THE SCHEDULE TO (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. The tender offer materials (including an Offer the offer to Purchasepurchase and related letter of transmittal), a related Letter as well as the solicitation/recommendation statement will be mailed to the Company’s stockholders free of Transmittal charge. Investors and certain other tender offer documents) stockholders may obtain free copies of the Schedule TO and the Solicitation/Recommendation Statement when they become available (Schedule 14D-9, as each may be amended or supplemented from time to time, and other documents filed by the parties (when available) because they will contain important information that holders of shares of Zynerba common stock should consider before making any decision regarding tendering their sharesat the SEC’s web site at wxx.xxx.xxx, by contacting the Company’s Investor Relations either by telephone at (000) 000-0000 or e-mail at ixxxxxxx.xxxxxxxxx@xxxxxxxxx.xxx or on the Company’s website at wxx.xxxxxxxxx.xxxxxxxxx.xxx. The Offer to Purchaseinformation contained in, or that can be accessed through, the Company’s website is not a part of, or incorporated by reference herein. In addition to an offer to purchase, a related Letter letter of Transmittal transmittal and certain other tender offer documents, as well as the Solicitationsolicitation/Recommendation Statementrecommendation statement, will be made available to all holders of shares of Zynerba at no expense to themthe Company files annual, quarterly and current reports, proxy statements and other information with the SEC. The tender offer materials and You may read any reports, statements or other information filed by the Solicitation/Recommendation Statement will be made available Company with the SEC for free at on the SEC’s website at wxx.xxx.xxx. In addition, these materials will be available at no charge on the Enhanced SEC Filings section of the Investor Relations page of Zxxxxxx’s website at wxx.xxxxxxx.xxx and by directing a request to the information agent for the tender offer, whose contact information will be set forth in the Offer to Purchase.